N V Naoumov

Summary

Affiliation: University College London
Country: UK

Publications

  1. ncbi request reprint Assessment and management of chronic hepatitis B
    Nikolai V Naoumov
    Institute of Hepatology, University College London, UCL Hospitals
    Clin Med 2:306-10. 2002
  2. ncbi request reprint Presence of a newly described human DNA virus (TTV) in patients with liver disease
    N V Naoumov
    Institute of Hepatology, Department of Medicine, University College London Medical School, UK
    Lancet 352:195-7. 1998
  3. ncbi request reprint Hepatitis C virus infection in Eastern Europe
    N V Naoumov
    Institute of Hepatology, University College London, England
    J Hepatol 31:84-7. 1999
  4. ncbi request reprint Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation
    N V Naoumov
    Institute of Hepatology, University College London and UCL Hospitals, UK
    J Hepatol 34:888-94. 2001
  5. ncbi request reprint Differentiation of core gene products of the hepatitis B virus in infected liver tissue using monoclonal antibodies
    N V Naoumov
    Institute of Hepatology, University College London Medical School, UK
    J Med Virol 53:127-38. 1997
  6. ncbi request reprint Non-cytolytic inhibition of hepatitis B virus replication in human hepatocytes
    D Suri
    Institute of Hepatology, University College London, 69-75 Chenies Mews, WC1E 6HX, London, UK
    J Hepatol 35:790-7. 2001
  7. ncbi request reprint Interferon plus amantadine versus interferon alone in the treatment of naïve patients with chronic hepatitis C: a UK multicentre study
    S Caronia
    Department of Medicine, St Mary's Hospital ICSM, London, UK
    J Hepatol 35:512-6. 2001
  8. doi request reprint Clinical trial: individualized treatment duration for hepatitis C virus genotype 1 with peginterferon-alpha 2a plus ribavirin
    K H Tang
    Institute of Hepatology, University College London, London, UK
    Aliment Pharmacol Ther 27:810-9. 2008
  9. pmc Comparison of real-time PCR assays for monitoring serum hepatitis B virus DNA levels during antiviral therapy
    Chee Kin Hui
    Department of Medicine, University of Hong Kong, Hong Kong, SAR, China
    J Clin Microbiol 44:2983-7. 2006
  10. ncbi request reprint Presence of hepatitis B virus core promoter mutations pre-seroconversion predict persistent viral replication after HBeAg loss
    R Bridget Ferns
    Centre for Virology, Department of Infection, University College, Windeyer Building, 46 Cleveland Street, London W1T 4JF, United Kingdom
    J Clin Virol 39:199-204. 2007

Collaborators

Detail Information

Publications33

  1. ncbi request reprint Assessment and management of chronic hepatitis B
    Nikolai V Naoumov
    Institute of Hepatology, University College London, UCL Hospitals
    Clin Med 2:306-10. 2002
  2. ncbi request reprint Presence of a newly described human DNA virus (TTV) in patients with liver disease
    N V Naoumov
    Institute of Hepatology, Department of Medicine, University College London Medical School, UK
    Lancet 352:195-7. 1998
    ..We investigated the presence of this virus in patients with liver disease in the UK to find out whether TTV infection is associated with liver damage...
  3. ncbi request reprint Hepatitis C virus infection in Eastern Europe
    N V Naoumov
    Institute of Hepatology, University College London, England
    J Hepatol 31:84-7. 1999
    ..This analysis aims to summarise the available information on the incidence, prevalence and characteristics of hepatitis C virus (HCV) infection in countries in Eastern Europe...
  4. ncbi request reprint Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation
    N V Naoumov
    Institute of Hepatology, University College London and UCL Hospitals, UK
    J Hepatol 34:888-94. 2001
    ..In a randomized trial we investigated a regimen where the initially given hepatitis B immunoglobulin (HBIg) is replaced by long-term lamivudine treatment...
  5. ncbi request reprint Differentiation of core gene products of the hepatitis B virus in infected liver tissue using monoclonal antibodies
    N V Naoumov
    Institute of Hepatology, University College London Medical School, UK
    J Med Virol 53:127-38. 1997
    ....
  6. ncbi request reprint Non-cytolytic inhibition of hepatitis B virus replication in human hepatocytes
    D Suri
    Institute of Hepatology, University College London, 69-75 Chenies Mews, WC1E 6HX, London, UK
    J Hepatol 35:790-7. 2001
    ..CONCLUSIONS: These results provide direct evidence that IFN-gamma can inhibit both HBV transcription and replication in human hepatocytes without cell lysis...
  7. ncbi request reprint Interferon plus amantadine versus interferon alone in the treatment of naïve patients with chronic hepatitis C: a UK multicentre study
    S Caronia
    Department of Medicine, St Mary's Hospital ICSM, London, UK
    J Hepatol 35:512-6. 2001
    ..05) while the sustained response was 18 and 15%, respectively. CONCLUSIONS: Combination therapy with interferon plus amantadine does not lead to a significant increase in sustained response rates when compared to interferon monotherapy...
  8. doi request reprint Clinical trial: individualized treatment duration for hepatitis C virus genotype 1 with peginterferon-alpha 2a plus ribavirin
    K H Tang
    Institute of Hepatology, University College London, London, UK
    Aliment Pharmacol Ther 27:810-9. 2008
    ..Individualized treatment regimens, taking into account the heterogeneity of patients with chronic hepatitis C, are needed to improve treatment outcomes...
  9. pmc Comparison of real-time PCR assays for monitoring serum hepatitis B virus DNA levels during antiviral therapy
    Chee Kin Hui
    Department of Medicine, University of Hong Kong, Hong Kong, SAR, China
    J Clin Microbiol 44:2983-7. 2006
    ..The results of the RealART and Digene Hybrid assays were related (r = 0.94; P < 0.001) and diverged by 2 orders of magnitude. The RealART assay can be used to effectively monitor serum hepatitis B virus DNA levels...
  10. ncbi request reprint Presence of hepatitis B virus core promoter mutations pre-seroconversion predict persistent viral replication after HBeAg loss
    R Bridget Ferns
    Centre for Virology, Department of Infection, University College, Windeyer Building, 46 Cleveland Street, London W1T 4JF, United Kingdom
    J Clin Virol 39:199-204. 2007
    ..In patients with chronic hepatitis B virus (HBV) infection DNA levels do not always fall after anti-hepatitis B e (anti-HBe) seroconversion...
  11. ncbi request reprint Genetic characteristics of hepatitis B virus genotypes as a factor for interferon-induced HBeAg clearance
    Jinlin Hou
    Institute of Hepatology, University College London, London WC1E 6HX, UK
    J Med Virol 79:1055-63. 2007
    ..The optimal duration of interferon-based therapies in chronic hepatitis B may vary between different HBV genotypes...
  12. ncbi request reprint Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B
    George K K Lau
    Department of Medicine, Queen Mary Hospital, Hong Kong SAR, China
    Antivir Ther 12:705-18. 2007
    ..The patterns of hepatitis B viral dynamics during different antiviral therapies and the associated changes in HBV-specific T-cell reactivity are not well defined...
  13. pmc Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivity
    Helen Cooksley
    Institute of Hepatology, University College London, 69 75 Chenies Mews, London WC1E 6HX, United Kingdom
    Antimicrob Agents Chemother 52:312-20. 2008
    ..In conclusion, T-cell reactivity to HBV increases in a proportion of ADV-treated patients and is associated with greater suppression of HBV replication and HBeAg loss...
  14. ncbi request reprint Telbivudine versus lamivudine in patients with chronic hepatitis B
    Ching Lung Lai
    University Department of Medicine, Queen Mary Hospital, Hong Kong, China
    N Engl J Med 357:2576-88. 2007
    ..Reducing hepatitis B virus (HBV) replication to minimal levels is emerging as a key therapeutic goal for chronic hepatitis B...
  15. doi request reprint APOBEC and iNOS are not the main intracellular effectors of IFN-gamma-mediated inactivation of Hepatitis B virus replication
    Sandra Proto
    Institute of Hepatology, University College London, and MRC Clinical Sciences Centre, Hammersmith Hospital, London WC1E 6HX, UK
    Antiviral Res 78:260-7. 2008
    ..We investigated the role of IFN-gamma-inducible nitric oxide synthase (iNOS) and APOBEC3 (A3) enzyme family in the inhibition of HBV replication by IFN-gamma...
  16. doi request reprint Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy
    Samreen Ijaz
    Virus Reference Department, Centre for Infections, Health Protection Agency, London, United Kingdom
    J Med Virol 80:1160-70. 2008
    ..The use of techniques such as Pyrosequencing provides an evidence-based approach for successful management of drug-resistant HBV...
  17. ncbi request reprint Chronic hepatitis B: a critical appraisal of current approaches to therapy
    Robert P Perrillo
    Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA
    Clin Gastroenterol Hepatol 4:233-48. 2006
    ..Expert opinions may differ from those of practicing hepatologists and gastroenterologists. We aimed to explore this issue further after a critical review of the literature...
  18. pmc Novel type of hepatitis B virus mutation: replacement mutation involving a hepatocyte nuclear factor 1 binding site tandem repeat in chronic hepatitis B virus genotype E
    Kei Fujiwara
    Department of Clinical Molecular Informative Medicine, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho, Nagoya 467 8601, Japan
    J Virol 79:14404-10. 2005
    ..This novel mutation may be specific to HBV genotype E, and its prevalence requires further investigation...
  19. ncbi request reprint Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity
    Eirini I Rigopoulou
    Institute of Hepatology, Division of Medicine, University College London, London, UK
    Hepatology 42:1028-36. 2005
    ..However, IL-12 does not abolish HBV replication in HBeAg-positive patients and does not maintain inhibition of HBV replication after lamivudine withdrawal...
  20. ncbi request reprint Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen
    George K K Lau
    Institute of Hepatology, University College London, London, England
    Gastroenterology 122:614-24. 2002
    ..We characterized HBV-specific T-cell responses in chronic hepatitis B surface antigen carriers who received bone marrow from HLA-identical donors with natural immunity to HBV and seroconverted to antibody to hepatitis B surface antigen...
  21. ncbi request reprint Translation of immunological knowledge into better treatments of chronic hepatitis B
    Antonio Bertoletti
    Institute of Hepatology, University College of London, London, UK
    J Hepatol 39:115-24. 2003
  22. ncbi request reprint Direct evidence that naturally occurring mutations within hepatitis B core epitope alter CD4+ T-cell reactivity
    Francesco Torre
    Institute of Hepatology, University College London, London, United Kingdom
    J Med Virol 72:370-6. 2004
    ....
  23. doi request reprint Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion
    Alexander Evans
    Institute of Hepatology, University College London, London, United Kingdom
    Hepatology 48:759-69. 2008
    ....
  24. ncbi request reprint A new intertype recombinant between genotypes C and D of hepatitis B virus identified in China
    Zhanhui Wang
    College of Life Science, Wuhan University, Wuhan, China
    J Gen Virol 86:985-90. 2005
    ..Hybrids of different HBV genotypes might exhibit specific virological properties and their significance in the diagnosis and management of chronic hepatitis B deserves further investigation...
  25. ncbi request reprint Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy
    Kwok H Tang
    Institute of Hepatology, University College London, 69 75 Chenies Mews, London WC1E 6HX, UK
    J Hepatol 43:776-82. 2005
    ..To gain understanding of inter-individual differences of treatment response in hepatitis C virus genotype 1 (HCV-G1) patients, we investigated simultaneously the early HCV kinetics and virus-specific T-cell reactivity...
  26. ncbi request reprint The potential of RNA interference as a tool in the management of viral hepatitis
    John A Taylor
    School of Biological Sciences, University of Auckland, Auckland, New Zealand
    J Hepatol 42:139-44. 2005
  27. ncbi request reprint Immunological techniques in viral hepatitis
    Barbara Rehermann
    Immunology Section, Liver Diseases Branch NIDDK, National Institutes of Health, DHHS, 10 Center Drive, Room 9B16, Bethesda, MD 20892, USA
    J Hepatol 46:508-20. 2007
    ..Our aim is to highlight topics and issues that were supported by general agreement and those that were controversial, as well as to provide suggestions for future work...
  28. ncbi request reprint Impact of NS5A sequences of Hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon- alpha 2a plus ribavirin
    Francesca Dal Pero
    Venetian Institute for Molecular Medicine, Padova, 35129, Italy
    J Infect Dis 196:998-1005. 2007
    ..Little is known about NS5A sequences of HCV-1a. We investigated whether genetic variability of HCV-1a NS5A correlates with the early HCV kinetics during treatment...
  29. ncbi request reprint Direct evidence for immunomodulatory properties of ribavirin on T-cell reactivity to hepatitis C virus
    Eirini I Rigopoulou
    Institute of Hepatology, University College London, 69 75 Chenies Mews, London WC1E 6HX, UK
    Antiviral Res 75:36-42. 2007
    ..Here we investigated whether ribavirin directly affects HCV-specific reactivity of CD4+T-lymphocytes from patients with CH-C...
  30. pmc Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions
    Ralf Schilling
    Institute of Hepatology, Department of Medicine, University College London, London WC1E 6HX, United Kingdom
    J Virol 77:8882-92. 2003
    ..These results suggest that HBs-specific IgG binds to hepatocytes and interacts with HBsAg within the cells. This may be relevant for the selection of surface antibody escape mutations...
  31. ncbi request reprint SEN viruses and treatment response in chronic hepatitis C virus
    Nikolai V Naoumov
    Lancet 359:1779-80; author reply 1780. 2002
  32. ncbi request reprint Individualization of antiviral treatment regimens for chronic hepatitis C
    Emma Paulon
    Institute of Hepatology, University College London, London, UK
    Eur J Gastroenterol Hepatol 18:321-5. 2006
    ..Accumulating evidence demonstrates that individualized treatment regimens, according to the timing of treatment-induced viral clearance, provide a safe and cost-effective approach, as well as an improvement in treatment efficacy...
  33. ncbi request reprint In vitro analysis of hepatitis B virus specific CD4+ T cells
    Shilpa Chokshi
    Institute of Hepatology, University College London, UK
    Methods Mol Med 96:97-109. 2004